Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy
Open Access
- 23 October 2007
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 7 (1), 197-9
- https://doi.org/10.1186/1471-2407-7-197
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non–Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy GroupJournal of Clinical Oncology, 2006
- Cytotoxicity of Docetaxel (Taxotere®) Used as a Single Agent and in Combination with Radiation in Human Gastric, Cervical and Pancreatic Cancer CellsChemotherapy, 2006
- Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancerBritish Journal of Cancer, 2006
- Clinical Pharmacokinetics of DocetaxelClinical Pharmacokinetics, 2006
- Phase III Study of Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Weekly Compared With 3-Weekly DocetaxelJournal of Clinical Oncology, 2005
- Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: A Phase I/II study with 5 years’ follow-upLung Cancer, 2005
- Prospective Evaluation of the Pharmacokinetics and Toxicity Profile of Docetaxel in the ElderlyJournal of Clinical Oncology, 2005
- Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinomaCancer, 2000
- Clinical Pharmacokinetics of DocetaxelClinical Pharmacokinetics, 1999
- Radiobiological effects of docetaxel (Taxotere): a potential radiation sensitizerInternational Journal of Radiation Biology, 1999